Leaning toward big wins in schizophrenia and vaccines, venture group raises new fund of $389 million

“We’re not talking about taking something from three pills to two pills, but a step change for patients,” says Pivotal BioVenture Partners’ Peter Bisgaard, of the kind of cures he hopes to back.
Click here to view original post